The sermorelin (5mg) + ghrp-2 (5mg) - blend is a dual-component research reagent designed for evaluating concurrent GHRH-receptor and GHS-R1a agonist signaling in laboratory models. Formulated in a precise 1:1 milligram ratio (5mg of each peptide per vial), this lyophilized compound enables high-precision in vitro and preclinical research into pituitary somatotroph secretagogue kinetics, intracellular messenger cross-talk, and pulsatile hormone release dynamics.
The sermorelin (5mg) + ghrp-2 (5mg) - blend is a dual-component research reagent designed for evaluating concurrent GHRH-receptor and GHS-R1a agonist signaling in laboratory models. Formulated in a precise 1:1 milligram ratio (5mg of each peptide per vial), this lyophilized compound enables high-precision in vitro and preclinical research into pituitary somatotroph secretagogue kinetics, intracellular messenger cross-talk, and pulsatile hormone release dynamics.
The sermorelin (5mg) + ghrp-2 (5mg) - blend combines two distinct secretagogue peptides: Sermorelin, an amino-terminal fragment of endogenous growth hormone-releasing hormone (GHRH 1-29), and GHRP-2 (Pralmorelin), a synthetic hexapeptide growth hormone secretagogue receptor (GHS-R1a) agonist. In preclinical investigation, pairing a GHRH-R agonist with a ghrelin receptor agonist allows researchers to study dual-pathway activation of anterior pituitary somatotrophs.
Synthesized under strict ISO 9001 and GMP-compliant conditions in USA facilities, each vial of the Sermorelin (5mg) + GHRP-2 (5mg) blend contains 5mg of Sermorelin acetate and 5mg of GHRP-2 acetate as a sterile, lyophilized cake. This dual-peptide formulation is strictly reserved for in vitro, cell culture, and animal research applications, providing a stable baseline for comparative receptor binding and downstream signaling assays.
To understand the biochemical utility of the sermorelin (5mg) + ghrp-2 (5mg) - blend, investigators analyze two independent yet convergent signal transduction pathways within anterior pituitary somatotrophic cells. Sermorelin functions specifically as a reference agonist for GHRH-receptor activation. Upon binding to the GHRH receptor—a G-protein coupled receptor (GPCR) paired with the Gs alpha subunit—Sermorelin stimulates adenylyl cyclase, raising intracellular cyclic adenosine monophosphate (cAMP) and activating protein kinase A (PKA). This cascade induces gene transcription of growth hormone and facilitates extracellular calcium entry through voltage-gated channels.
Conversely, GHRP-2 targets the growth hormone secretagogue receptor type 1a (GHS-R1a), a distinct GPCR coupled to the Gq/11 subunit. Activation by GHRP-2 triggers phospholipase C (PLC) activity, generating inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilization induces rapid intracellular calcium release from the endoplasmic reticulum. When evaluated together, preclinical studies suggest that simultaneous stimulation of Gs (via Sermorelin) and Gq (via GHRP-2) yields a supra-additive or synergistic signal for pulsatile hormone secretion compared to single-agent treatments.
Sermorelin represents the fully active truncated peptide sequence corresponding to the first 29 amino acids of human GHRH: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2. It possesses a molecular formula of C149H246N44O42S and a molecular weight of 3357.88 Da. Its primary structural identity renders it a standard reference compound for studying GHRH-R binding kinetics and peptide degradation kinetics in biological matrices.
GHRP-2 is a synthetic hexapeptide with the sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2, boasting a molecular formula of C45H55N9O6 and a molecular weight of 817.97 Da. The inclusion of D-amino acid residues (D-Ala, D-2-Nal, D-Phe) provides substantial resistance to enzymatic cleavage by circulating exopeptidases and endopeptidases in experimental media. In the PX1 Research co-lyophilized blend, both compounds are stabilized with mannitol matrix support to preserve peptide tertiary structure and prevent aggregation during storage.
Preclinical studies across rodent models, porcine pituitary explants, and cell culture assays have documented the distinct characteristics of combined GHRH-R and GHS-R activation. Experimental data demonstrate that while GHRH analogs such as Sermorelin 5mg establish physiological pulsatility, GHS-R agonists like GHRP-2 5mg amplify the amplitude of secretory pulses. When co-administered in vitro, the combined signal bypasses negative feedback loops mediated by somatostatin (SRIF) more effectively than either compound independently.
Research literature further reveals that GHRP-2 exhibits minor cross-reactivity with hypothalamic pathways governing appetite signaling and ACTH release in animal models due to its ghrelin-mimetic profile. Researchers studying receptor crosstalk often measure extracellular calcium fluxes, cAMP production rates, and downstream IGF-1 transcription markers to map out the specific intracellular contributions of each component within the blend.
In peptide research, selecting the optimal secretagogue combination depends on the specific receptors and kinetics under investigation. The sermorelin (5mg) + ghrp-2 (5mg) - blend is often evaluated alongside alternative combinations such as the CJC-1295 / Ipamorelin Blend or individual non-selective agonists like GHRP-6 5mg.
While CJC-1295 (without DAC) paired with Ipamorelin 5mg offers an extremely selective GHS-R activation profile with minimal impact on cortisol or prolactin pathways, the Sermorelin + GHRP-2 combination provides a classic benchmark. GHRP-2 exhibits higher potency in stimulating total hormone output in pituitocytes than Ipamorelin, albeit with moderate activity on secondary ghrelin-mediated axes. Compared to standalone growth hormone releasing hormone analogs, dual blends allow research teams to assess cross-pathway desensitization and receptor co-localization in a single experimental model.
To ensure precise volumetric dosing in laboratory experiments, proper reconstitution protocols must be observed. Lyophilized peptides should be allowed to equilibrate to room temperature before handling to prevent condensation inside the vial. Reconstitution should be performed under a laminar flow hood using sterile bacteriostatic water for laboratory reconstitution (0.9% benzyl alcohol preserved) or sterile laboratory-grade phosphate-buffered saline (PBS, pH 7.4).
For a 1:1 blend containing 5mg of Sermorelin and 5mg of GHRP-2 (10mg total peptide mass), adding 2.5 mL of diluent yields a final concentration of 2mg/mL of Sermorelin and 2mg/mL of GHRP-2 (4mg/mL total combined peptide). Diluent should be introduced slowly along the glass wall of the vial, followed by gentle swirling. Vortexing or vigorous shaking must be avoided to prevent shear stress, peptide denaturation, or hydrophobic aggregation. For further details on handling standards, reference our detailed growth hormone secretagogue mechanisms research guide.
Lyophilized vials of the sermorelin (5mg) + ghrp-2 (5mg) - blend remain stable for up to 24 months when stored at -20°C in a desiccated freezer. For long-term archival storage, temperature stability is maximized at -80°C. Vials should be protected from direct light exposure to prevent photo-oxidation of sensitive amino acid residues, particularly Tryptophan (Trp4 in GHRP-2) and Methionine (Met27 in Sermorelin).
Once reconstituted, aqueous peptide solutions should be stored at 2°C to 8°C and utilized within 28 days if preserved with bacteriostatic water. Unpreserved saline reconstitutions must be used immediately or aliquoted into single-use microcentrifuge tubes and frozen at -80°C to minimize degradation from repeated freeze-thaw cycles. Laboratories managing high-throughput screens can review chemical storage specifications in our comprehensive PX1 Research chemical library.
PX1 Research maintains rigorous purity standards for all custom and off-the-shelf research compounds. Every lot of the sermorelin (5mg) + ghrp-2 (5mg) - blend undergoes independent, third-party analytical verification at an ISO 17025 accredited testing facility. Chromatographic purity is quantified via Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring each individual peptide component meets or exceeds 99.0% chemical purity.
Exact molecular weights are validated using Electrospray Ionization Mass Spectrometry (ESI-MS) to confirm identity and verify the absence of truncated sequences or counter-ion impurities. Additionally, bacterial endotoxin testing via Chromogenic Limulus Amebocyte Lysate (LAL) assays ensures endotoxin levels remain below 0.01 EU/mg, protecting delicate cell cultures and animal models from endotoxin-induced inflammatory responses. Complete lot-specific Certificates of Analysis (COAs) are published openly for full research transparency.
PX1 Research is dedicated to supplying verified, high-purity compounds to academic institutions, biotechnology firms, and independent research laboratories across the United States. All products are manufactured in GMP-compliant, USA-based facilities adhering to rigid quality assurance protocols. Orders are packaged under temperature-monitored conditions and shipped directly from our primary distribution hubs in California and Arizona, with same-day fulfillment offered Monday through Friday.
Principal investigators and laboratory managers seeking bulk inventory, custom blend formulations, or corporate billing accounts can visit our dedicated wholesale research account hub or consult the main peptide research hub for technical documentation and analytical specifications. All items, including the sermorelin (5mg) + ghrp-2 (5mg) - blend, are provided strictly for in vitro and laboratory research applications.
What is the primary research utility of the Sermorelin (5mg) + GHRP-2 (5mg) blend?
The blend is designed for laboratory research investigating the dual stimulation of GHRH receptors (via Sermorelin) and GHS-R1a ghrelin receptors (via GHRP-2). It allows researchers to analyze synergistic intracellular pathways (cAMP and IP3/DAG) in pituitary cell cultures and preclinical animal models.
What is the ratio of peptides in the Sermorelin + GHRP-2 blend vial?
Each vial contains a 1:1 ratio by mass: 5mg of Sermorelin acetate and 5mg of GHRP-2 acetate, yielding 10mg of total active peptide mass in a co-lyophilized state.
How does GHRP-2 differ from Sermorelin in mechanism?
Sermorelin is a GHRH(1-29) analog that acts on GHRH receptors to activate Gs-protein/cAMP pathways. GHRP-2 is a synthetic hexapeptide agonist of the GHS-R1a receptor that activates Gq-protein/PLC pathways, stimulating intracellular calcium release.
What diluent should be used for reconstituting the blend for cell culture?
For cell culture and short-term in vitro assays, sterile 0.9% sodium chloride or sterile phosphate-buffered saline (PBS) is recommended. For multi-use laboratory procedures requiring extended stability at 4°C, sterile bacteriostatic water (0.9% benzyl alcohol) is typically utilized.
How is the purity of the Sermorelin + GHRP-2 blend verified by PX1 Research?
Purity is verified through third-party ISO 17025 accredited laboratory testing using RP-HPLC (confirming >99% purity for both components) and ESI-MS (confirming exact molecular mass). Endotoxin levels are also tested via LAL assay (<0.01 EU/mg).
How should the reconstituted Sermorelin + GHRP-2 blend be stored?
Reconstituted solutions should be stored at 2°C to 8°C and protected from light. Solutions in bacteriostatic water remain stable for up to 28 days at refrigerated temperatures. For long-term liquid storage, aliquots should be frozen at -80°C to avoid repeated freeze-thaw cycles.
Where is PX1 Research peptide manufacturing located?
All PX1 Research peptides are manufactured in state-of-the-art, GMP-compliant facilities located within the USA, with fulfillment dispatched from CA and AZ warehouses.
Is the Sermorelin (5mg) + GHRP-2 (5mg) blend suitable for human use or clinical administration?
No. All products sold by PX1 Research, including the Sermorelin (5mg) + GHRP-2 (5mg) blend, are strictly intended for laboratory research and in vitro testing. They are not for human or animal consumption, diagnostic use, or therapeutic application.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.